CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
Aminolevulinic Acid Topical 20% Topical Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03322293
NCT03322293Phase 1Completed
CompareCT.gov

Tolerability and Efficacy of Daylight Aminolevulinic-acid-photodynamic Therapy (ALA-PDT) Compared With Conventional ALA-PDT for Treatment of Actinic Keratosis on the Face or Scalp

University of California, San Francisco·interventional·Posted Oct 26, 2017·Updated Mar 9, 2022

In Brief

A Phase 1 clinical trial evaluating Aminolevulinic Acid Topical 20% Topical Solution and BLU-U blue light phototherapy illuminator for Actinic Keratoses. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This is a randomized, single-blind controlled trial with parallel group design to determine whether daylight photodynamic therapy (PDT) affords a reduction in treatment symptoms of pain, burning, and pruritus as measured by 1) symptom level during the treatment period and 2) pain at the end of treatment exposure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratoses
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedOct 26, 2017
Enrollment StartDec 1, 2017
Primary CompletionDec 1, 2018
Study CompletionJul 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 8.7 years ago

Interventions

Aminolevulinic Acid Topical 20% Topical Solutiondrug

PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).

BLU-U blue light phototherapy illuminatordevice

Depending on the treatment arm, subjects will either receive BLU-U exposure or not. Treatment arms A and B have BLU-U exposure and treatment arm C does not.